Our first episode features former Biogen and Alexion CFO, Paul Clancy, who was recognized in the top three biotech CFOs by Institutional Investor from 2011-2020, and was awarded the number five Top CFO by the Wall Street Journal, across all industries. The discussion centers on Paul’s experience navigating investor activists while confronting the unique challenges of allocating capital, innovation, and marketing resources with long development cycles.
Listen to the podcast here or watch on Youtube.
The podcasts is also available on other platforms, including Pandora, Stitcher, and Amazon.